Global Point of Care Diagnostics Market Outlook
Revenue, 2024
$15.7B
Forecast, 2034
$38.3B
CAGR, 2025 - 2034
9.3%
The Point of Care Diagnostics industry revenue is expected to be around $17.2 billion in 2025 and expected to showcase growth with 9.3% CAGR between 2025 and 2034. The current perspective supports Point of Care Diagnostics as an essential tool for value based and decentralized healthcare because it enables clinicians to make faster clinical decisions which shortens hospital stays and leads to better results through immediate data based treatments in hospital rooms and clinics. The combination of increasing infectious diseases and chronic diseases and aging populations and patient centered healthcare models drives demand for faster diagnostic solutions which payers and providers now consider essential for their care delivery systems.
Point of Care Diagnostics, POC Diagnostics, consists of portable diagnostic systems which perform fast testing and produce medical results directly at patient locations through user friendly interfaces and built in quality control systems and clinical system connectivity. The solutions operate across various healthcare settings including emergency departments and intensive care units and physician offices and pharmacies and home care environments to perform tests for infectious diseases and cardiac markers and glucose monitoring and coagulation assessment and pregnancy testing and chronic disease management. The healthcare market continues to adopt new technologies which include digital displays and smartphone compatible analyzers and cloud based data analysis and workflow optimization systems to expand diagnostic capabilities and maintain long term market growth in established and developing healthcare sectors.
Market Key Insights
The Point of Care Diagnostics market is projected to grow from $15.7 billion in 2024 to $38.3 billion in 2034. This represents a CAGR of 9.3%, reflecting rising demand across Hospital Settings, Clinical Laboratories, and Home Self-Testing.
Roche, Abbott, and Danaher are among the leading players in this market, shaping its competitive landscape.
The Point of Care Diagnostics market leads with the United States and China as its main customer bases which will experience 6.8% to 9.8% annual growth rates from 2024 to 2030.
The market research predicts that India, Brazil and South Korea will experience the fastest growth among emerging markets at a combined annual rate of 8.9% to 11.6%.
Transition like Convergence With Digital Health is expected to add $3 billion to the Point of Care Diagnostics market growth by 2030
.The Point of Care Diagnostics market will experience $22.5 billion growth during 2024-2034 because manufacturers focus on serving Ambulatory Care Facilities and Physician Offices & Hospitals Application.
With
integration of digital health ecosystems and miniaturized biosensor innovation transforming point of care diagnostics, and
Growing global burden of chronic diseases accelerating adoption of point of care diagnostics in community settings, Point of Care Diagnostics market to expand 143% between 2024 and 2034.
Opportunities in the Point of Care Diagnostics
The three regions of India Brazil and Sub Saharan Africa use infectious disease Point of Care Diagnostics to address essential primary care needs. The global market for Infectious Disease Testing Products will also expand from 5.52 billion in 2024 to 8.89 billion by 2030 at an 8.26% annual growth rate from 2025 to 2030. Rural clinics now use decentralized diagnostics and rapid diagnostic tests because governments and NGOs support their deployment for laboratory free operations. The market will see its highest expansion through infectious disease testing products and respiratory point of care testing platforms which will drive growth in community and mobile health programs.
Growth Opportunities in North America and Asia-Pacific
The adoption of Point of Care Diagnostics in North America starts with hospitals and critical care centers and urgent care facilities because these settings need fast diagnostic results for their acute care operations and value based payment systems. The main business potential exists in uniting near patient testing equipment with electronic health records and analytics systems to create decentralized diagnostic capabilities for emergency departments and satellite clinics. The market competition exists between established manufacturers and data driven new entrants who focus on connectivity while differentiating through molecular point of care menus and workflow automation and enterprise level service models. The investment strategy should concentrate on developing networkable systems which combine with high sensitivity assays for cardiology and sepsis diagnosis and antimicrobial stewardship programs.
The Asia Pacific region experiences Point of Care Diagnostics expansion because ambulatory care facilities and physician offices drive growth while community clinics and pharmacy based services expand healthcare access to remote region's. The market demands affordable rugged near patient testing solutions and home based testing kits for chronic disease monitoring and maternal health and infectious disease screening. The market competition between local manufacturers and international suppliers remains high because companies need to produce products locally while maintaining flexible pricing and building strong distributor networks to succeed. The strategic investment should focus on portable molecular point of care systems and decentralized diagnostics models which match government primary care and telemedicine programs.
Market Dynamics and Supply Chain
01
Driver: Integration of digital health ecosystems and miniaturized biosensor innovation transforming Point of Care Diagnostics
Point of Care Diagnostics gain increased value through digital health ecosystem integration which enables real time data exchange with electronic health records and telemedicine platforms and clinical decision support tools for better care coordination and decentralized healthcare delivery. The connection between portable analyzers and mobile health applications and cloud analytics systems enables clinicians to combine patient data from rapid testing workflows for better risk assessment and treatment planning in primary care and emergency settings. The development of miniaturized biosensors has also created lab on a chip systems and molecular point of care assays which provide laboratory quality results during bedside or home based testing. The combination of microfluidics with nanomaterials and integrated detection systems reduces device size while increasing test capabilities for multiplex infectious disease detection and chronic disease management which leads to increased adoption of advanced Point of Care Diagnostics in various healthcare settings.
The increasing number of diabetes and cardiovascular and respiratory diseases patients continues to drive up demand for Point of Care Diagnostics tools which enable continuous monitoring outside hospital laboratories. Healthcare organizations focus on developing fast testing solutions for community clinics and pharmacies and physician offices to identify disease worsening at an early stage and stop unnecessary hospital admissions. The combination of glucometers and cardiac biomarkers and inflammatory marker assays with wearable sensors and remote monitoring programs allows healthcare providers to better manage patients who face high risks. The ongoing management of chronic diseases has also led healthcare organizations to allocate funds for affordable testing solutions that operate outside central laboratories which makes Point of Care Diagnostics essential for value based care and population health management initiatives.
02
Restraint: Fragmented regulatory frameworks delay approvals and increase compliance costs for innovative Point of Care Diagnostics
The approval process for rapid diagnostic tests and molecular point of care platforms becomes delayed because of different regulatory paths and ongoing guideline modifications and complicated post market monitoring requirements which forces companies to prolong clinical testing periods and increase costs and postpone their ability to generate revenue; Small decentralized diagnostic manufacturers choose to focus on lower regulation markets which results in reduced test options and decreased market demand for hospital emergency departments and primary care POC testing locations.
03
Opportunity: Rising adoption of Point of Care Diagnostics for home based chronic disease management in North America and Advanced cardiometabolic and coagulation Point of Care Diagnostics transforming emergency and critical care workflows in European hospitals
The increasing number of elderly North Americans who live with diabetes and hypertension and dyslipidemia outside hospitals drives the development of home based Point of Care Diagnostics. The global market for Glucose Monitoring Products reached 5.92 billion in 2024 and experts predict it will reach 10.04 billion by 2030 while showing a 9.2% annual growth rate from 2025 to 2030. The market growth follows increasing patient needs for home based testing and remote monitoring and smart POC devices which connect directly to electronic health records. The market will experience its highest growth rate from glucose monitoring products while cardiometabolic and cholesterol testing solutions will follow closely behind.
European hospitals now focus on Point of Care Diagnostics which help clinicians speed up their triage process for patients with chest pain and stroke and sepsis. The worldwide market for Cardiometabolic Monitoring Products will expand from 4.28 billion in 2024 to 7.87 billion by 2030 while maintaining a 10.7% annual growth rate from 2025 to 2030. The integration of near patient testing with real time decision support dashboards occurs through strategic partnerships between diagnostics manufacturers and hospital networks and digital health vendors. The market segment of cardiometabolic and coagulation monitoring analyzers for emergency and intensive care units will experience the fastest growth rates.
04
Challenge: Reimbursement uncertainty and pricing pressures undermine sustainable profitability for advanced Point of Care Diagnostics solutions
Healthcare providers select less expensive laboratory tests because of inconsistent coverage decisions and reimbursement reductions and bundled payment systems which limits their ability to adopt premium Point of Care Diagnostics in outpatient clinics. The market shift toward basic assays leads manufacturers to experience reduced profit margins while new POC platform development slows down which limits long term market growth despite increasing clinical requirements for near patient testing.
Supply Chain Landscape
1
Component Sourcing
Thermo Fisher ScientificMerck Group3M Health Care
2
Point of Care Diagnostics
RocheAbbottDanaher
3
Decentralized Testing Distribution
Cardinal HealthMcKessonCencora
4
End-User
HospitalsClinical laboratoriesHome healthcare
1
Component Sourcing
Thermo Fisher ScientificMerck Group3M Health Care
2
Point of Care Diagnostics
RocheAbbottDanaher
3
Decentralized Testing Distribution
Cardinal HealthMcKessonCencora
4
End-User
HospitalsClinical laboratoriesHome healthcare
Use Cases of Point of Care Diagnostics in Hospital Settings & Clinical Laboratories
Hospital Settings : The Point of Care Diagnostics market generates 4.99 billion dollars from hospital end users during 2024 and experts predict this segment will expand at 9.7% annually until 2030 because hospitals need fast bedside diagnostic tests to make quick medical choices and enhance patient results. The two main product categories in hospital settings are Cardiometabolic Monitoring Products and Infectious Disease Testing Products which together account for 62.35% of total market demand because they help doctors identify respiratory pathogens and sepsis and evaluate acute chest pain. The hospital information systems receive real time results through Roche and Abbotts CLIA waived analyzer portfolios and integrated connectivity systems which Abbott and Roche use to maintain their market leadership. The company achieves market differentiation through its advanced blood gas and molecular point of care testing systems which operate within critical care environments. The hospital operations through its reliable specimen collection systems and safety engineered devices and decentralized diagnostics that help standardize infection management protocols. The company bioMrieux leads the market through its microbiology expertise and antimicrobial stewardship solutions which enable emergency and intensive care units to perform near patient testing for better hospital operations and quality and stewardship performance.
Clinical Laboratories : The Point of Care Diagnostics market depends on clinical laboratories as its main customer base because they spent 3.03 billion in 2024 and will continue to grow at 7.7% annually from 2025 to 2030 through their deployment of compact analyzers in satellite labs and outreach sites to reduce testing time while maintaining centralized quality control. The healthcare networks use Infectious Disease Testing Products and Cardiometabolic Monitoring Products to handle urgent samples and large scale screening programs while Glucose Monitoring Products support diabetes care and chronic disease management in outpatient settings. The combination of immunochemistry and hematology testing systems from Roche and Abbott provides strong performance in this application because they enable standardized results across multiple lab sites through their connectivity ready point of care testing systems. The company Danaher provides competitive advantage through its molecular point of care testing platforms which operate within core laboratory systems and integrated middleware platforms. BD supports clinical laboratory operations through pre analytical solutions and flexible analyzers which protect sample quality for decentralized testing applications. The bioMrieux company leads the market for infectious disease and microbiology panels which allows laboratories to perform near patient testing in community and ambulatory collection centers while maintaining their high diagnostic performance.
Home Self-Testing : The home care sector along with self testing applications drive Point of Care Diagnostics revenue growth at 2.56 billion in 2024 with a projected 10.6% annual expansion rate until 2030 because of aging populations and chronic disease management and consumer preference for private testing solutions. The market leader in Point of Care Diagnostics is Glucose Monitoring Products because they make up 37.65% of total demand while Cardiometabolic Monitoring Products and Infectious Disease Testing Products gain popularity through user friendly devices that enable fast diagnostic testing with app support. Home self testing enables patients to monitor their health continuously which allows them to share test results with doctors for better treatment adherence and fewer unnecessary medical facility visits. The main benefit of home self testing allows patients to monitor their health continuously which enables them to share test results with doctors for better treatment adherence and fewer unnecessary medical facility visits. Abbott and Roche maintain their leadership position through their wide range of connected glucose meters and self testing solutions which deliver precision and user friendly operation and digital connectivity. The market access expansion of BD and Danaher depends on their development of dependable sampling systems and portable analyzers which provide safe and uncomplicated operation for non professional users. bioMrieux expands its market dominance through the development of user friendly infectious disease testing solutions which enable point of care testing to move from medical facilities into residential region's to support expanded preventive healthcare initiatives and earlier disease detection.
Recent Developments
The current POC Diagnostics market shows fast growing acceptance of quick diagnostic solutions which serve emergency facilities and retail clinics and home healthcare settings. The development of microfluidics and biosensors and portable molecular diagnostics systems leads to better test results and shorter testing periods and enhanced electronic health record integration. The market shows growing interest in decentralized testing for infectious diseases and chronic disease management through digital health platforms and remote patient monitoring systems.
October 2023 : Roche announced its final agreement to acquire LumiraDxs Point of Care Diagnostics platform and associated assets which will enhance Roches worldwide Point of Care Diagnostics reach through its high sensitivity immunoassay POC testing for cardiology and infectious diseases. The acquisition will boost competition in decentralized and near patient testing solutions which operate between hospital facilities and primary care centers.
April 2023 : The FDA granted Abbott clearance to use its i STAT TBI Plasma test for whole blood rapid testing to help doctors assess concussions directly at patient bedsides. The FDA clearance for the i STAT TBI Plasma test enables point of care blood testing for mild traumatic brain injury assessment in emergency and urgent care facilities which will probably boost adoption of sophisticated Point of Care Diagnostics tools and fast testing methods for neurological emergency evaluation and critical care management.
Impact of Industry Transitions on the Point of Care Diagnostics Market
As a core segment of the Medical Device industry,
the Point of Care Diagnostics market develops in line with broader industry shifts.
Over recent years, transitions such as Convergence With Digital Health and At Home and Retail Expansion have redefined priorities
across the Medical Device sector,
influencing how the Point of Care Diagnostics market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Convergence With Digital Health
The Point of Care Diagnostics market is undergoing a transformative shift from standalone rapid testing devices to integrated, data driven systems that seamlessly connect with digital health platforms. This evolution enables real time transmission of test results to electronic health records and telemedicine systems, empowering healthcare providers to conduct immediate risk assessments and monitor patients remotely. As vendors develop secure API connections and validate algorithms within flexible cloud based infrastructures, the strategic integration of these technologies is projected to drive an additional $3 billion in market growth by 2030. Furthermore, pharmaceutical companies are leveraging decentralized diagnostic data to refine clinical trial participant selection and enhance drug safety monitoring, thereby optimizing real world evidence collection across diverse treatment categories. This convergence not only enhances patient care but also positions the market for significant expansion in the coming years. This industry transition is expected to add $3 billion in the industry revenue between 2024 and 2030.
02
At Home and Retail Expansion
The healthcare industry now provides Point of Care Diagnostics through home based and retail clinic locations which has accelerated decentralized diagnostic services for primary care and chronic disease management. The availability of affordable near patient testing and compact molecular assays in pharmacies and employer clinics and community health programs has created a disruption in the traditional reference laboratory model. The service models of retailers and logistics providers and consumer health brands need to handle quality assurance and cold chain distribution and user friendly packaging to support earlier detection and better treatment adherence and lower healthcare expenses for people who lack access to care.